POLYCHELATING AGENT INCORPORATION LIPOSOMES &MICELLES

Information

  • Research Project
  • 6016557
  • ApplicationId
    6016557
  • Core Project Number
    R43CA083458
  • Full Project Number
    1R43CA083458-01
  • Serial Number
    83458
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/1999 - 25 years ago
  • Project End Date
    2/29/2000 - 24 years ago
  • Program Officer Name
    TORRES-ANJEL, MANUEL J.
  • Budget Start Date
    9/1/1999 - 25 years ago
  • Budget End Date
    2/29/2000 - 24 years ago
  • Fiscal Year
    1999
  • Support Year
    1
  • Suffix
  • Award Notice Date
    8/27/1999 - 25 years ago

POLYCHELATING AGENT INCORPORATION LIPOSOMES &MICELLES

A novel polymeric probe capable of chelating multiple metal atoms (In, Gd) and suitable for the incorporation into liposomes and micelles will be synthesized and tested in vitro. A new molecule represents low-molecular- weight DTPA-polylysine linked via its N-terminus to a lipid anchor, NGPE-PE (DTPA-PLL-PE). In a preliminary experiment, we demonstrated here that liposomes containing 3 mole % of new membrane- bound polychelator and loaded with Gd possess enhanced relaxivity for water protons when compared with liposomes loaded with Gd via known membranotropic DTPA-SA and DTPA-PE. Liposomes will be prepared with variable contents of DTPA-PLL-PE and polyethylene glycol-PE (PEG-PE) and optimized in terms of their relaxivity and stability towards blood plasma. PED-PE-based micelles will be prepared containing variable quantities of DTPA-PLL-PE will be prepared. Their relaxivity and stability will be studied upon loading with Gadolinium. PROPOSED COMMERCIAL APPLICATIONS: Currently there are no vascular imaging agents marketed for Magnetic Resonance Imaging. There are 8 million cases of coronary artery disease per year of which there are one million scans estimated for this population. A MRI angiography contrast agent would have a large potential market in the USA alone.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    394
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
  • Organization Name
    BIOSTREAM THERAPEUTICS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    CAMBRIDGE
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02142
  • Organization District
    UNITED STATES